BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23151911)

  • 1. Comparison of PET metabolic indices for the early assessment of tumour response in metastatic colorectal cancer patients treated by polychemotherapy.
    Maisonobe JA; Garcia CA; Necib H; Vanderlinden B; Hendlisz A; Flamen P; Buvat I
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):166-74. PubMed ID: 23151911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer.
    Buvat I; Necib H; Garcia C; Wagner A; Vanderlinden B; Emonts P; Hendlisz A; Flamen P
    Eur J Nucl Med Mol Imaging; 2012 Oct; 39(10):1628-34. PubMed ID: 22710958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
    Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
    Lastoria S; Piccirillo MC; Caracò C; Nasti G; Aloj L; Arrichiello C; de Lutio di Castelguidone E; Tatangelo F; Ottaiano A; Iaffaioli RV; Izzo F; Romano G; Giordano P; Signoriello S; Gallo C; Perrone F
    J Nucl Med; 2013 Dec; 54(12):2062-9. PubMed ID: 24136935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer.
    Heijmen L; de Geus-Oei LF; de Wilt JH; Visvikis D; Hatt M; Visser EP; Bussink J; Punt CJ; Oyen WJ; van Laarhoven HW
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1858-67. PubMed ID: 22945372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET scans as a predictive marker of survival in advanced colorectal cancer.
    Choi M; Kollepara SL; Heilbrun LK; Smith D; Shields AF; Philip PA
    Clin Colorectal Cancer; 2015 Mar; 14(1):35-40. PubMed ID: 25481195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of sequential 18(F) -FDG PET/CT in predicting tumour response after preoperative chemoradiation for rectal cancer.
    Sun W; Xu J; Hu W; Zhang Z; Shen W
    Colorectal Dis; 2013 May; 15(5):e231-8. PubMed ID: 23384167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
    Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
    Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standardized added metabolic activity (SAM): a partial volume independent marker of total lesion glycolysis in liver metastases.
    Mertens J; Dobbeleir A; Ham H; D'Asseler Y; Goethals I; Van de Wiele C
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1441-8. PubMed ID: 22699529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
    Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy.
    Hendlisz A; Golfinopoulos V; Garcia C; Covas A; Emonts P; Ameye L; Paesmans M; Deleporte A; Machiels G; Toussaint E; Vanderlinden B; Awada A; Piccart M; Flamen P
    Ann Oncol; 2012 Jul; 23(7):1687-93. PubMed ID: 22112970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma.
    Sager S; Akgün E; Uslu-Beşli L; Asa S; Akovali B; Sahin O; Yeyin N; Demir M; Abuqbeitah M; Gülsen F; Sayman H; Sönmezoglu K
    Nucl Med Commun; 2019 May; 40(5):461-468. PubMed ID: 30896544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
    Odawara S; Kitajima K; Katsuura T; Kurahashi Y; Shinohara H; Yamakado K
    Eur J Radiol; 2018 Apr; 101():65-71. PubMed ID: 29571803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Quantitative Methods on FDG PET/CT for Treatment Response Evaluation of Metastatic Colorectal Cancer.
    Bang JI; Lim Y; Paeng JC; Han SW; Park S; Lee JM; Kim HJ; Cheon GJ; Lee DS; Chung JK; Kim TY; Kang KW
    Nucl Med Mol Imaging; 2017 Jun; 51(2):147-153. PubMed ID: 28559939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis.
    Orlhac F; Soussan M; Maisonobe JA; Garcia CA; Vanderlinden B; Buvat I
    J Nucl Med; 2014 Mar; 55(3):414-22. PubMed ID: 24549286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma.
    Im HJ; Kim TS; Park SY; Min HS; Kim JH; Kang HG; Park SE; Kwon MM; Yoon JH; Park HJ; Kim SK; Park BK
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):39-49. PubMed ID: 21953008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma.
    Kim YI; Cheon GJ; Paeng JC; Cho JY; Kang KW; Chung JK; Kim EE; Lee DS
    Nucl Med Commun; 2014 Jun; 35(6):606-12. PubMed ID: 24598843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher predictive value of tumour and node [18F]-FDG PET metabolic volume and TLG in advanced lung cancer under chemotherapy.
    Olivier A; Petyt G; Cortot A; Scherpereel A; Hossein-Foucher C
    Nucl Med Commun; 2014 Sep; 35(9):908-15. PubMed ID: 24785008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and predictive role of [
    Zucali PA; Lopci E; Ceresoli GL; Giordano L; Perrino M; Ciocia G; Gianoncelli L; Lorenzi E; Simonelli M; De Vincenzo F; Setti LR; Bonifacio C; Bonomi M; Bombardieri E; Chiti A; Santoro A
    Cancer Med; 2017 Oct; 6(10):2287-2296. PubMed ID: 28941158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.
    Shady W; Kishore S; Gavane S; Do RK; Osborne JR; Ulaner GA; Gonen M; Ziv E; Boas FE; Sofocleous CT
    Eur J Radiol; 2016 Jun; 85(6):1224-31. PubMed ID: 27161074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.